Trial Profile

Prospective, Multicenter, Open-Label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Receiving Axicabtagene Ciloleucel (Yescarta)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Defibrotide (Primary)
Indications Chemotherapy-induced damage; Drug toxicity; Neurotoxicity syndrome
Focus Therapeutic Use
Sponsors Jazz Pharmaceuticals plc

16 Apr 2021 Planned End Date changed from 1 May 2021 to 18 Dec 2020.
16 Apr 2021 Planned primary completion date changed from 1 Apr 2021 to 14 Aug 2020.
16 Apr 2021 Status changed from recruiting to discontinued as primary endpoints would be unlikely to be met based on the unplanned interim assessment on the first 20 efficacy evaluable patients.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com